GLYCATED ALBUMIN ASSAY MARKET ANALYSIS

Regional Analysis

Global Glycated Albumin Assay Market- Regional Analysis

Among region, North America is expected to dominate the market over the forecast period. This is attributed to increasing adoption of inorganic growth strategies, such as company acquisitions by key players in the region to expand their product portfolio. This is expected to drive the market growth over the forecast period. For instance, in July , LifeSpan BioSciences, a leading provider of antibodies and life science research reagents announced its acquisition of Everest Biotech, certified experts in antigen affinity purified goat polyclonal antibodies which will help LifeSpan BioSciences to develop new technologies for glycated albumin assay.

European region is expected to hold the second largest market share over the forecast period, owing to increasing prevalence of chronic kidney diseases in this region, which can use glycated albumin for the diagnosis of kidney diseases, which is expected to drive the market growth over the forecast period. For instance, in February 2022, European parliament stated that in Europe, 100 million people suffer from chronic kidney diseases, and predictions suggest that it will become the fifth leading cause of death globally by 2040.

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC Countries, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa